
Novel single-chain peptide mimetics, B7-33, for the treatment of fibrosis
Fibrosis and related disorders are among the leading causes of death worldwide highlighting the need for more direct and improved anti-fibrotic strategies.
We have shown in animal models that H2 relaxin has therapeutic potential for fibrosis and related disorders.
However, the H2 peptide has a complex insulin-like 2 chain structure with three disulphide bonds and short plasma half-life that makes the peptide expensive to manufacture and less effective as a long-term drug treatment. In a major breakthrough published in Chemical Science (flagship journal, Royal Society of Chemistry) we discovered a single-chain variant of H2 relaxin (B7-33) which has no disulfide bridges, and which is easy to manufacture and modify to improve its in vivo plasma half-life.
B7-33 was shown to specifically bind the relaxin receptor, RXFP1, and preferentially activate pathways related to anti-fibrotic effects in fibroblast in vitro and in rats and mouse models of fibrosis in vivo without side effects.
Thus, B7-33 represents the first single-chain functionally-selective agonist of RXFP1. In the proposed study, we will unravel the pharmacological basis of functional selectivity of B7-33.
Additionally we will test if B7-33 is able to mimic other actions of H2 relaxin related to heart failure. We will further modify and optimise our current lead B7-33 by using rational structure-based drug design and medicinal chemistry techniques (stapling, lipidation etc) to improve in vivo half-life. Finally B7-33 and stabilised analogs will be tested in clinically relevant experimental models of cardiac fibrosis to confirm their potential for translation as an anti-fibrotic agent.
Support us
Brain health affects all Australians. You can support our research by making a donation or a bequest.
- Give todayDonate now
- Pledge over timeJoin our brains trust
- Plan for the futureMake a gift in your will
Newsletter
Latest breakthroughs, news, events & more.